Intelligence Platform

Patents

Browse 19 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12275937

Stereospecific linkages in RNA editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12203072

Chemically modified single-stranded rna-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180471

Antisense oligonucleotides for the treatment of Stargardt disease

ProQR Therapeutics II B.V. · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018257

Single-stranded RNA-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11920132

Oligonucleotide therapy for Leber congenital amaurosis

ProQR Therapeutics II B.V. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851656

Chemically modified single-stranded RNA-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649454

Single-stranded RNA-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479771

Antisense oligonucleotides for the treatment of eye disease

ProQR Therapeutics II B.V. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11123360

Oligonucleotides to treat eye disease

ProQR Therapeutics II B.V. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10988763

Single-stranded RNA-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941402

Chemically modified single-stranded RNA-editing oligonucleotides

ProQR Therapeutics II B.V. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10900041

Antisense oligonucleotides for use in treating Alzheimer's disease

ProQR Therapeutics II B.V. · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10889817

Oligonucleotide therapy for Leber Congenital Amaurosis

ProQR Therapeutics II B.V. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10760076

Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic dis

ProQR Therapeutics II B.V. · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10617707

Oligonucleotides to treat eye disease

ProQR Therapeutics II B.V. · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10612025

Antisense oligonucleotides for the treatment of eye disease

ProQR Therapeutics II B.V. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421963

Oligonucleotide therapy for leber congenital amaurosis

ProQR Therapeutics II B.V. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9994856

Method for increasing the activity of a cystic fibrosis transmembrane conductance regulato

ProQR Therapeutics II B.V. · Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605255

Oligonucleotides for making a change in the sequence of a target RNA molecule present in a

ProQR Therapeutics II B.V. · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted